RSS Alerts

Events & Training for January 2016

Social Media in the Pharmaceutical Industry

20 January 2016 - 21 January 2016

As well as social media leading the way in pharmacovigilance, clinical trial recruitment and digital marketing, the pharmaceutical industry is entering into a new and exciting digital era which is embracing patient engagement through sophisticated use of ‘social listening' and playing a central role in cutting edge personalised healthcare such as wearable technology. Bringing in voices from industry experts and leading pharmaceutical companies including Actelion, Bristol-Myers Squibb, Boehringer Ingelheim, Lundbeck, Creation Healthcare, Novo Nordisk, Pfizer and Roche, the 8th annual conference on Social Media in the Pharmaceutical Industry, will provide a niche platform for senior marketing practitioners to capture the latest trends and technologies, learn from practical case studies and benchmark best practice to maximise digital strategy. For details visit http://www.social-media-pharma.com/ddt

Holiday Inn Kensington Forum, London, UK

Pharmaceutical Microbiology

20 January 2016 - 21 January 2016

This event is about the developments in the field of pharmaceutical Microbiology. Pharmaceutical microbiology is crucial to the manufacture and production of drugs, biologics and devices. Without a strong understanding of the process from case studies and learning from mistakes it can be incredibly costly. Set to take place in Central London on the 20th-21st January 2016 the 5th annual pharmaceutical biology will once again be bringing together industry leaders and key figures in the field to discuss and develop a greater understanding of key issues and regulations.

Holiday Inn Kensington Forum, London, UK

8th Immunotherapeutics & Immunomonitoring Conference

25 January 2016 - 26 January 2016

The immune system plays a central role not only in fighting infections, but also in many diseases and medical conditions, including cancer. Studies of the immune system has led to significant findings in many fields of medicine and biology, which has yielded the discovery of novel and unique substances and reagents that are now widely used for diagnosing, evaluating, and treating different malignant diseases. The development of prophylactic and therapeutic vaccines, and innovative combinatorial immunotherapeutic approaches, has substantially decreased mortality, increased life expectancy, improved life expectancy and improved the well-being of the millions of patients. Leading experts from the scientific and clinical arenas and industry will present novel findings and developments in the constantly-changing area of immunological assays and procedures. They will also discuss recent advances in immunotherapy as they relate to various immunotherapy modalities, specific cancers, cell subsets, animal models, and tumor microenvironment. Potential clinical feasibility and commercial potential of the newest data obtained from leading biomedical research laboratories will also be discussed. Network with colleagues to discuss updates on state-of-the-art immunomonitoring, novel strategies to identify and validate biomarkers predictive for clinical efficacy, novel strategies to identify and clinically develop synergistic combination therapies, and the outlook on novel druggable targets for immunotherapy.

Paradise Point Resort & Spa, San Diego, CA, USA

14th Cytokines & Inflammation Conference

25 January 2016 - 26 January 2016

Over the years, GTCbio’s Cytokines & Inflammation Conference has become an established meeting point for academic scientists, industry clinical developers, and government researchers to discuss complementary approaches in the field of cytokine biology. We are excited to announce the 14th annual edition of this meeting, which will take place January 25-26, 2016 in San Diego, CA, so mark your calendars and save the date!

Paradise Point Resort & Spa, San Diego, CA 92109, USA

3rd Allergy, Asthma, & COPD Conference

25 January 2016 - 26 January 2016

This meeting provides a forum for researchers in the field to share advances in topics ranging from basic scientific research to biomarkers and clinical development. We will take a look at diseases such as eosinophilic esophagitis and atopic dermatitis, along with disorders involving comorbidities like ACOS. Another area of interest includes biomarkers for understanding phenotypes in allergic diseases. This meeting is the ideal event for networking and discussion on progress towards therapeutic potential in these disease areas.

Paradise Point Resort & Spa, San Diego, CA 92109, USA

Pre Filled Syringes

27 January 2016 - 28 January 2016

The device and drug delivery market is continuing to grow exponentially with the likes of pre-filled pen systems, auto-injectors and patch pumps continuing to pave the way to enhancing drug delivery of biologics. Figures show that despite challenges relating to drug stability, manufacturing and competition from other drug delivery technologies, the market is poised for significant growth in the coming years and will account for nearly $6 Billion in revenue by the end of 2020.* Although glass continues to remain the gold standard for pre-filled syringes, the proportion of plastic based pre-filled syringes is expected to increase by 5% between 2015 and 2020*, due to concerns of glass breakage and plunger failure. It’s time to start reviewing packaging and device design in more depth, from technology and market drivers to challenges and strategies within the supply chain.

The Copthorne Tara Hotel, London Kensington, London, UK

Hypnosis & Psychosomatic Medicine Section. To Sleep Perchance to Dream

07 March 2016

The aim of this meeting is to develop a greater understanding of the nature of dreams, including the neurophysiology of dreaming, the role of dreams, dream content and interpretation, cultural perspectives and the development of lucid dreaming. Dr Kate Adams, Bishop Grossteste University, will open the meetings with a discussion on the religious and spiritual dreams of children. Anthropologist Dr Iain Edgar, Durham University, will discuss his study of Jihad and the dreams of Islamic State. Dr David Kraft, British Society of Clinical and Academic Hypnosis, will investigate the relevance and use of dream interpretation in clinical practice. The meeting will end with a presentation by Robert Schapira, President, RSM Hypnosis & Psychosomatic Medicine Section, who will talk about the induction of lucid dreaming by transcranial stimulation of the prefrontal cortex.

Royal Society of Medicine 1 Wimpole Street LONDON W1G 0AE

The future of psychiatry: Big data, new media and the digital revolution

08 March 2016

Digital technology in medicine is starting to change our health, defining the way we live, the way we understand mental illness and the way we will deliver healthcare in the future. This meeting aims to present ideas that show how big data is revolutionising health policy and collaborative research. The psychopathology of the Internet age will be explored. New digital therapeutics will be discussed, together with how our digital identity is managed. Speakers will include Professor Sean Hill who will present the work of the Human Brain Project and Professor Matthew Hotopf, King’s College Hospital, London, who will lead a discussion on the big data revolution in clinical care. Professor Ulrike Schmidt, King’s College, London, will talk about how social media are shaping body image and eating disorders and Dr Henrietta Bowden-Jones, Imperial College, London, will discuss Internet addiction. Professor Tom Craig, King’s College London will lead a session on AVATAR therapy and how it can help silence voices in schizophrenia and Dr Alys Cole-King, Royal College of Psychiatrists, will discuss social media, technology and suicide prevention. The meeting will end with a session on the benefits of Twitter for psychiatrists led by Dr Alex Langford, Oxford Health NHS Foundation Trust.

Royal Society of Medicine 1 Wimpole Street LONDON W1G 0AE

Rio 2016 Olympic Games: The impact of sport and exercise nutrition

10 March 2016

In the lead up to the 2016 Olympic Games in Rio, this meeting brings together some of the world’s leading researchers and practitioners to highlight the latest advances in sports nutrition. The meeting will discuss how nutrition is used within elite performance and how these concepts can be translated for the general public. Mr James Moore, Deputy Chef de Mission, British Olympic Association, will open the meeting with some reflections from London 2012 and challenges for Rio 2016. Discussing the science of performance nutrition will be Dr James Morton, Liverpool John Moores University and Team Sky; Dr Lewis James, Loughborough University and Dr Graeme Close, Liverpool John Moores University and nutritionist for England Rugby. Discussion of the practical applications will be led by Mr Michael Naylor, The English Institute of Sport and England Rugby, together with Dr Ken Van Someren of the GSK Human Performance Lab and Dr Steve Ingham, Director of Science and Technical Development, The English Institute of Sport. A panel discussion on working as a team will be led by Mr James Collins, President, RSM Food & Health Forum and participants will include a Team GP Olympic Athlete (name to be confirmed pending training schedules), Dr Benjamin Rosenblatt and Miss Emma Gardner, GB Hockey and The English Institute of Sport.

Royal Society of Medicine 1 Wimpole Street LONDON W1G 0AE

Medicine and Me: Living well with dementia

15 March 2016

The Medicine and Me series of meetings gives a direct voice to patients and their carers to air their concerns on the impact of diagnosis, investigation and management of important conditions. The audience at this meeting will comprise of those living with dementia, their families, carers and advocates, representing about 70% of those present; and researchers and clinicians including doctors, specialist nurses and others involved in the treatment and care of those living with dementia.

Royal Society of Medicine 1 Wimpole Street LONDON W1G 0AE

Hot topics in vaccine preventable diseases

15 March 2016

This meetings aims to present an A-Z guide to the epidemiology, surveillance and management of vaccine preventable infections. A panel of speakers who are leaders in their field will give an update on the national childhood immunisation programme and the current epidemiology of the infectious diseases that the programme aims to prevent. Topics covered will also include the role of the National Infection Service and Health Protection Teams in supporting clinicians looking after children with suspected vaccine preventable infections, the clinical management of confirmed vaccine failures and new childhood vaccines on the horizon.

Royal Society of Medicine 1 Wimpole Street LONDON W1G 0AE

Training today: NHS 7-day services

15 March 2016

This meeting will review the government’s aim to expand NHS services in England across seven days. This vision is unique amongst G20 nations, and a panel of eminent speakers and key stakeholders will convene to discuss the details, the merits and the challenges of an evolving plan that will likely represent one of the greatest service changes since the inception of the NHS in 1948. Workforce issues will be discussed by Professor Charles Easmon, University of West London. Paul Aylin, Professor of Epidemiology and Public Health and Co-Director of the Dr Foster Unit, Imperial College London, will discuss the evidence for the ‘weekend effect’. Dr Helen Bevan, Chief Transformation Officer, NHS Horizons Group, will talk about implementing change in the the NHS, and the economics of 7-day access will be presented by Matt Sutton, Professor of Health Economics, University of Manchester.

Royal Society of Medicine 1 Wimpole Street LONDON W1G 0AE

Alzheimer's Disease Therapeutics - are we making progress towards a disease modifying treatment for patients?

10 June 2016

Alzheimer’s disease is arguably the largest healthcare issue of our time, with over 45 million people currently diagnosed with dementia worldwide. With the single biggest risk factor being age, this number is only going to increase as our populations’ age. The human impact of this is huge for patients and their families, but the financial impact to our health care systems is also going to be enormous. In the US alone, Alzheimer’s disease is the 6th leading cause of death, with over 5.4 million people affected and health care costs in excess of $400 billion and expected to rise to over $1 trillion by 2050. Alzheimer’s disease pathology is highly complex, but is believed to be principally the result of an inter-play between the toxic proteins beta-amyloid and tau and driven by several genetic and environmental risk factors. Current treatments focus on treating cognitive and behavioural symptoms but have only modest effects and duration of efficacy. Alzheimer’s disease has no cure or even therapeutics which slows the progression of this disease, although a number are currently in clinical development. So it is clear that there is a huge need to find treatment options for patients and their families. While considerable resources have been directed towards finding “disease modifying” drugs by multiple pharmaceutical and biotechnology companies, the results from several large clinical trials have been mixed. This symposium will look at the progress that the field has made over recent years in attempting to target different aspects and stages of Alzheimer’s disease pathology and what lessons have been learned. It will also look at the current biological mechanisms under clinical and pre-clinical evaluation, together with exploring how new and developing genetic insights into the disease are directing us to novel mechanisms for potential new treatment options. Leading experts from industry and academia have been brought together for an exciting symposium to review, challenge and debate this complex disease biology and to address the critical question - “Are we making progress towards a disease modifying treatment for patients?”

'Living Tomorrow' Conference Centre Indringingsweg 1, 1800 Vilvoorde, Brussels, Belgium

Society for Medicines Research "Rare Diseases, Extraordinary Aspirations"

13 October 2016

Orphan drugs are designated drug substances that are intended to treat rare or ‘orphan’ diseases which are classified as less than 200,000 total individual cases in the US and a rate of <5 in 10,000 individuals in the EU. More than 7000 rare diseases are known that collectively affect some 6-7% of the developed world’s population. 75% of patients are children, a third of whom will die before they reach the age of 5 years old. In the case of cancer, all but the four most common indications fall under the orphan disease definition. Given this, the cancer community normally classifies “rare cancers” as those with an incidence of less than 6 per 100,000 persons per year. Individually any single rare disease may only affect a handful of people making them a relatively unattractive prospect for the biopharmaceutical industry to target. However, ground breaking legislation starting with the Orphan Drug Act that was passed in the US in 1983 now provides financial incentives for companies to develop orphan drugs sparking ever increasing interest from biopharmaceutical companies to tackle rare diseases. Today, rare diseases and the drugs that treat them are sufficiently attractive that many companies and research institutes now have research units dedicated to this area of research. It is therefore timely to review the area of orphan drugs and some of the basic science, drug discovery and regulatory factors that underpin this important, and growing, area of biomedical research. This meeting brings together experts from academia, industry and disease advocacy organisations working in the rare disease field to present their experiences and thoughts on tackling rare diseases through case studies and opinion pieces. This promises to be an exciting and interesting meeting with in depth discussion of how the drug discovery and development community has approached rare disease research in the past and how this will evolve in the future to allow broader access to rare disease therapeutics. It will provide an excellent networking environment for anyone interested in this important research area.

National Heart and Lung Institute, Dovehouse Street London SW3 6LY

Emerging Paradigms in Drug Discovery & Chemical Biology

25 October 2016

Chemical Biology is changing the face of drug discovery. Over the past decade, chemistry based approaches have facilitated unprecedented advances in our understanding of cell biology and animal physiology, and have proven highly useful for drug discovery, demonstrating success not only in target and mechanism identification, but also in target validation and off-target identification. This symposium will highlight recent advances in on-target and off-target identification of drug-protein interactions in physiologically relevant systems, and will feature talks on the ubiquitin proteasome system, GPCRs, protein lipidation mechanisms, neurobiology, and cancer.

The New York Academy of Sciences

Copyright © 2024
Elsevier Ltd. All rights reserved.
Sitemap | Terms & Conditions | Privacy | | Website Design Working with water